Blue Owl Capital Holdings’s enGene Therapeutics Warrants ENGNW Stock Holding History

Blue Owl Capital Holdings’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.29M	Buy	511,177 +475,077	+1,316%	+$1.41M	0.35%	35
2025 Q4	$103K	Hold	36,100	–	–	0.03%	51
2025 Q3	$25.6K	Hold	36,100	–	–	0.01%	55
2025 Q2	$29.6K	Hold	36,100	–	–	0.01%	54
2025 Q1	$21.7K	Hold	36,100	–	–	0.01%	53
2024 Q4	$30.4K	Sell	36,100 -475,077	-93%	-$701K	0.01%	55
2024 Q3	$728K	Buy	511,177 +460,000	+899%	+$543K	0.14%	48
2024 Q2	$608K	Sell	51,177 -460,000	-90%	-$1.47M	0.17%	36
2024 Q1	$2.66M	Buy	511,177 +36,100	+8%	+$110K	0.53%	31
2023 Q4	$404K	Buy	+475,077	New	+$365K	0.1%	38

Other funds holding ENGNW

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LMR Partners London, United Kingdom $10.9B AUM 60.68% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.36B AUM 24.94% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Saba Capital Management New York $3.12B AUM 13% 1-Year Est. Return

CSS LLC Chicago, Illinois $1.8B AUM 59.56% 1-Year Est. Return

Ionic Capital Management New York $119M AUM 48.26% 1-Year Est. Return

Clear Street New York $17.8B AUM 56.26% 1-Year Est. Return